Armend Håti
Founder
ClexBio
ClexBio develops VivoSet™ technology to create fully vascularized therapeutic tissues that restore lost cell and organ function by providing a supportive microenvironment for embedded therapeutic cells. This approach addresses the critical shortage of viable organ transplants and offers new treatment options for chronic diseases like Type 1 diabetes and advanced liver disease.
- Biotechnology
Updated 2 months ago
Funding
Raised to date
$2.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
AIEFG1Not disclosed · Undisclosed
Announced Nov 2024
Disclosed cumulative: $2.2M
2/2
RoundDateAmountValuationInvestors
Founders
Product
Problem
Current treatments for chronic diseases and organ failure often fall short of fully restoring lost cell and organ function. The shortage of viable organ transplants and the limitations of traditional cell therapies highlight the need for innovative therapeutic approaches.
Solution
ClexBio is developing VivoSet™ technology, a platform for creating fully vascularized therapeutic tissues designed to restore lost cell and organ function. These bioengineered tissues provide a supportive microenvironment for embedded therapeutic cells, promoting long-term functionality and integration with the host environment. By engineering tissues with perfusible microvascular networks, ClexBio ensures rapid engraftment and efficient exchange of nutrients and therapeutic products. The tissues are entirely cell-synthesized, eliminating artificial materials and reducing the risk of fibrotic responses. This approach offers a potential solution for chronic diseases like Type 1 diabetes, advanced liver disease, and heart disease, where traditional treatments have limitations.
Target Audience
The primary target audience includes researchers and clinicians focused on regenerative medicine, cell therapy, and tissue engineering, as well as patients with chronic diseases such as Type 1 diabetes, advanced liver disease and heart disease.
Features
- VivoSet™ technology enables the creation of fully vascularized therapeutic tissues.
- Engineered with microvascular networks for rapid engraftment and anastomosis with host vasculature.
- Cell-synthesized extracellular matrix (ECM) eliminates artificial materials and reduces fibrotic responses.
- Tissues are loaded with function-specific therapeutic cells, supported by a holistic multicellular architecture.
- Designed to restore lost cell and organ function in chronic diseases.